Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

13.56 -0.26 (-1.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 213,379
Open 13.72
Bid (Size) 13.55 (800)
Ask (Size) 13.59 (1,400)
Prev. Close 13.82
Today's Range 13.35 - 13.74
52wk Range 7.562 - 18.98
Shares Outstanding 24,296,259
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NeuroPace to Present at the Leerink Global Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
News headline image
Why NeuroPace Stock Was Inching Higher on Wednesday ↗
The company finished 2025 with a convincing pair of earnings beats. 
Via The Motley Fool

Performance

YTD
-10.6%
-10.6%
1 Month
-12.4%
-12.4%
3 Month
-13.2%
-13.2%
6 Month
+37.1%
+37.1%
1 Year
+18.9%
+18.9%

More News

Read More
News headline image
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
NeuroPace Inc (NASDAQ:NPCE) Beats Q4 2025 Estimates and Reiterates 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace (NPCE) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
News headline image
Integer Holdings (ITGR) Shares Plunge 31.4% as Slower New Product Adoption and Revised Guidance Rock Investor Confidence
Via MarketMinute
Topics Earnings Supply Chain
News headline image
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Participate in Upcoming Healthcare Conferences
From NeuroPace, Inc.
Via Business Wire

Frequently Asked Questions

Is Neuropace, Inc. - Common Stock publicly traded?
Yes, Neuropace, Inc. - Common Stock is publicly traded.
What exchange does Neuropace, Inc. - Common Stock trade on?
Neuropace, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neuropace, Inc. - Common Stock?
The ticker symbol for Neuropace, Inc. - Common Stock is NPCE on the Nasdaq Stock Market
What is the current price of Neuropace, Inc. - Common Stock?
The current price of Neuropace, Inc. - Common Stock is 13.56
When was Neuropace, Inc. - Common Stock last traded?
The last trade of Neuropace, Inc. - Common Stock was at 03/18/26 04:00 PM ET
What is the market capitalization of Neuropace, Inc. - Common Stock?
The market capitalization of Neuropace, Inc. - Common Stock is 329.46M
How many shares of Neuropace, Inc. - Common Stock are outstanding?
Neuropace, Inc. - Common Stock has 329M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.